The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration

Thrombosis and Haemostasis

Volumn 78, Issue 4, 1997, Pages 1202-1208

  Kjalke, Marianne ^a,c   Oliver, Julie A ^a,b   Monroe, Dougald M ^a   Hoffman, Maureane ^b   Ezban, Mirella ^c   Hedner, Ulla ^c   Roberts, Harold R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 7A; PADGEM PROTEIN; THROMBIN; THROMBOPLASTIN; THROMBOXANE A2;

ADULT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 0030699224     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657715     Document Type: Article

References (55)

1. Camerer E, Kolstø A-B, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
2. Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a "prima ballerina". Thromb Haemost 1995; 74: 7-17.
3. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989; 134: 1087-97.
4. Fleck RA, Rao LVM, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990; 59: 421-37.
5. Flössel C, Luther T, Müller M, Albrecht S, Kasper M. Immunohistochemical detection of tissue factor (TF) on paraffin sections of routinely fixed human tissue. Histochemistry 1994; 101: 449-53.
6. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
7. Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992; 11: 249-66.
8. Sørensen BB, Persson E, Freskgård P-O, Kjalke M, Ezban M, Williams T, Rao LVM. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272: 11863-8.
9. Ørvim U, Barstad RM, Örning L, Petersen LB, Ezban M, Hedner U, Sakariassen KS. Inactivated active site recombinant FVIIa is an efficient inhibitor of tissue factor FVIIa induced arterial thrombus formation in human blood. Thromb Haemost 1995; 73: 1185.
10. Kirchhofer D, Tschopp TB, Baumgartner HR. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler Thromb Vasc Biol 1995; 15: 1098-106.
11. Harker LA, Hanson SR, Kelly AB. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995, 74; 464-72.
12. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26 (suppl. 1): 76-82.
13. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit artherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-50.
14. Arnljots B, Ezban M, Hedner U. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. J Vasc Surg 1997; 25: 341-6.
15. Goodnight SH. Antiplatelet therapy with aspirin: From clinical trials to practice. Thromb Haemost 1995; 74: 401-5.
16. Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: Theory and practice. Blood 1994; 83: 885-98.
17. 2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem 1990; 265: 6836-44.
18. Szczeklik A, Krzanowski M, Góra P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood 1992; 80: 2006-11.
19. Kessels H, Béguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood - the effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83.
20. Bjornsson TD, Schneider DE, Berger Jr. H. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989; 250: 154-61.
21. Hampton KK, Cerletti C, Loizou LA, Bucchi F, Donati MB, Davies JA, de Gaetano G, Prentice CRM. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1200 mg daily compared with placebo. Thromb Haemost 1990; 64: 17-20.
22. Monroe DM, Roberts HR, Hoffman M. Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol 1994; 88: 364-71.
23. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 1995; 86: 1794-1801.
24. Church FC, Meade JB, Treanor RE, Whinna HC. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. J Biol Chem 1989; 264: 3618-23.
25. Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Moeller KB, Meidahl-Pedersen J, Beck TC, Norris K, Hedner U, Kisiel W. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 265: 16786-93.
26. Thim L, Bjoern S, Christensen M, Nicolaisen EM, Lund-Hansen T, Pedersen AH, Hedner U. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785-93.
27. Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 71: 629-35.
28. Oliver JA, Hoffman M, Monroe DM, Ezban M, Hedner U, Roberts HR. Active site-inhibited coagulation factor VIIa blocks platelet activation, thrombin generation, and accumulation of platelet-bound factor X in a tissue factor-initiated system. Blood 1995; 86 (suppl. 1): 77a.
29. Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coag Fibrinol 1996; 7: 459-64.
30. Kurachi K, Fujikawa K, Schmer G, Davie EW. Inhibition of bovine factor IXa and factor Xaβ by antithrombin III. Biochemistry 1976; 15: 373-7.
31. Kaiser B, Koza M, Walenga JM, Fareed J. Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb Res 1996; 82: 257-63.
32. 2+-binding site in the serine protease domain of human factor VIIa and its role in tissue factor binding and development of catalytic activity. J Biol Chem 1995; 270: 15523-30.
33. Krishnaswamy S. The interaction of human factor VIIa with tissue factor. J Biol Chem 1992; 267: 23696-706.
34. Broze GJ. Binding of human factor VII and VIIa to monocytes. J Clin Invest 1982; 70: 526-35.
35. Drake TA, Ruf W, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109: 389-95.
36. Ruf W, Kalnik MW, Lund-Hansen T, Edgington T. Characterization of factor VII association with tissue factor in solution. High and low affinity calcium binding sites in factor VII contribute to functionally distinct interactions. J Biol Chem 1991; 266: 15719-25.
37. Ruf W, Miles DJ, Rehemtulla A, Edgington TS. Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex. J Biol Chem 1992; 267: 6375-81.
38. Chang GTG, Kisiel W. Internalization and degradation of recombinant human coagulation factor VIIa by the human hepatoma cell line HuH7. Thromb Haemost 1995; 73: 231-8.
39. Sakai T, Lund-Hansen T, Paborsky L, Pedersen AH, Kisiel W. Binding of human factors VII and VIIa to human bladder carcinoma cell line (J82). Implications for the initiation of the extrinsix pathway of blood coagulation. J Biol Chem 1989; 264: 9980-8.
40. Nemerson Y, Gentry R. An ordered addition, essential activation model of the tissue factor pathway of coagulation: Evidence for a conformational cage. Biochemistry 1986; 25: 4020-33.
41. Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995; 74: 180-4.
42. Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968; 47: 2169-80.
43. Kumar R, Ansell JE, Canoso RT, Deykin D. Clinical trial of a new bleeding-time device. Am J Clin Pathol 1978; 70: 642-5.
44. Mielke CH, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204-15.
45. Fiore LD, Brophy MT, Lopez A, Janson P, Deykin D. The bleeding time response to aspirin. Identifying the hyperresponder. Am J Clin Pathol 1990; 94: 292-6.
46. Ryan WL, Hakenkamp K. Variable response to aspirin measured by platelet aggregation and bleeding time. Lab Med 1991; 22: 197-202.
47. Young VP, Giles AR, Pater J, Corbett WEN. Sex differences in bleeding time and blood loss in normal subjects following aspirin administration. Thromb Res 1980; 20: 705-9.
48. Holmsen H. Platelet secretion and energy metabolism. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, third edition. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. J. B. Lippincott Company, Philadelphia, 1994; pp 524-45.
49. Rand ML, Perry DW, Packham MA, Gemmell CH, Yeo EL, Kinlough-Rathbone RL. Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: Direct measurements of percent release of β-thromboglobulin and assessment by flow cytrometry of P-selectin expression. Am J Hematol 1996; 52: 288-94.
50. Chronos NAF, Wilson DJ, Janes SL, Hutton RA, Buller NP, Goodall AH. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of α-granules or lysosomes from, human platelets. Clin Sci 1994; 87: 575-80.
51. Braun M, Kramann J, Strobach H, Schrör K. Incomplete inhibition of platelet secretion by low-dose aspirin. Platelets 1994; 5: 325-31.
52. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet a-granule release. Blood 1993; 82: 505-12.
53. Chen LY, Nichols WW, Mattson C, Teger-Nilson A-C, Wallin R, Saldeen TGP, Metha JL. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis. Cardiovascular Res 1995; 30: 866-74.
54. Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Coll Cardiol 1993; 22: 296-301.
55. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang I-K, Holt R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-22.